NCT00256100

Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.

Assessment of the Safety and Efficacy of Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Renal Failure.

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Melbourne Health · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this project is to assess the safety and effectiveness of fondaparinux, a new drug to prevent blood clotting in the continuous dialysis machine used in intensive care patients who have kidney failure.

Detailed description

The study hypothesis is that when used as an anticoagulant in haemofiltration, fondaparinux prolongs the filter life when compared to enoxaparin. Fondaparinux is the first compound of a new class of synthetic oligosaccharides with antithrombotic effects. It represents the active portion of the natural heparin molecule. The null hypothesis is that there is no difference in filter life when using fondaparinux or enoxaparin as anticoagulation for haemofiltration.

Conditions

• Renal Failure

Interventions

Type	Name	Description
DRUG	Fondaparinux Sodium	The active group of the study will be given fondaparinux 10mg/24 hours for haemofiltration anticoagulation

Timeline

• Start date: 2004-06-01
• Primary completion: 2007-12-01
• Completion: 2007-12-01
• First posted: 2005-11-21
• Last updated: 2017-04-12

Locations

1 site across 1 country: Australia